310 related articles for article (PubMed ID: 15341595)
21. Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1.
Martin NI; Derbyshire ER; Marletta MA
Bioorg Med Chem Lett; 2007 Sep; 17(17):4938-41. PubMed ID: 17587571
[TBL] [Abstract][Full Text] [Related]
22. YC-1 potentiates cAMP-induced CREB activation and nitric oxide production in alveolar macrophages.
Hwang TL; Tang MC; Kuo LM; Chang WD; Chung PJ; Chang YW; Fang YC
Toxicol Appl Pharmacol; 2012 Apr; 260(2):193-200. PubMed ID: 22381622
[TBL] [Abstract][Full Text] [Related]
23. Molecular variants of soluble guanylyl cyclase affecting cardiovascular risk.
Wobst J; Rumpf PM; Dang TA; Segura-Puimedon M; Erdmann J; Schunkert H
Circ J; 2015; 79(3):463-9. PubMed ID: 25746521
[TBL] [Abstract][Full Text] [Related]
24. Role of sulfhydryl-dependent dimerization of soluble guanylyl cyclase in relaxation of porcine coronary artery to nitric oxide.
Zheng X; Ying L; Liu J; Dou D; He Q; Leung SW; Man RY; Vanhoutte PM; Gao Y
Cardiovasc Res; 2011 Jun; 90(3):565-72. PubMed ID: 21248051
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of YC-1-induced activation of soluble guanylyl cyclase.
Friebe A; Koesling D
Mol Pharmacol; 1998 Jan; 53(1):123-7. PubMed ID: 9443939
[TBL] [Abstract][Full Text] [Related]
26. Generation and characterization of a stable soluble guanylate cyclase-overexpressing CHO cell line.
Becker EM; Wunder F; Kast R; Robyr C; Hoenicka M; Gerzer R; Schröder H; Stasch JP
Nitric Oxide; 1999; 3(1):55-66. PubMed ID: 10355896
[TBL] [Abstract][Full Text] [Related]
27. Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells.
El-Sehemy A; Chang AC; Azad AK; Gupta N; Xu Z; Steed H; Karsan A; Fu Y
Cell Signal; 2013 Dec; 25(12):2780-7. PubMed ID: 24041655
[TBL] [Abstract][Full Text] [Related]
28. Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft.
Berkan O; Bagcivan I; Kaya T; Yildirim K; Yildirim S; Doğan K
Can J Physiol Pharmacol; 2007 May; 85(5):521-6. PubMed ID: 17632587
[TBL] [Abstract][Full Text] [Related]
29. YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells.
Liu XM; Peyton KJ; Mendelev NN; Wang H; Tulis DA; Durante W
Mol Pharmacol; 2009 Jan; 75(1):208-17. PubMed ID: 18923065
[TBL] [Abstract][Full Text] [Related]
30. Endurance training upregulates the nitric oxide/soluble guanylyl cyclase/cyclic guanosine 3',5'-monophosphate pathway in the striatum, midbrain and cerebellum of male rats.
Chalimoniuk M; Chrapusta SJ; Lukačova N; Langfort J
Brain Res; 2015 Aug; 1618():29-40. PubMed ID: 26006108
[TBL] [Abstract][Full Text] [Related]
31. Differentiation of cGMP-dependent and -independent nitric oxide effects on platelet apoptosis and reactive oxygen species production using platelets lacking soluble guanylyl cyclase.
Rukoyatkina N; Walter U; Friebe A; Gambaryan S
Thromb Haemost; 2011 Nov; 106(5):922-33. PubMed ID: 21800013
[TBL] [Abstract][Full Text] [Related]
32. Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition.
Garthwaite G; Goodwin DA; Neale S; Riddall D; Garthwaite J
Mol Pharmacol; 2002 Jan; 61(1):97-104. PubMed ID: 11752210
[TBL] [Abstract][Full Text] [Related]
33. Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application.
Nakane M
Clin Chem Lab Med; 2003 Jul; 41(7):865-70. PubMed ID: 12940510
[TBL] [Abstract][Full Text] [Related]
34. Regional distribution of protein and activity of the nitric oxide receptor, soluble guanylyl cyclase, in rat brain suggests multiple mechanisms of regulation.
Nedvetsky PI; Kleinschnitz C; Schmidt HH
Brain Res; 2002 Sep; 950(1-2):148-54. PubMed ID: 12231239
[TBL] [Abstract][Full Text] [Related]
35. Nucleotidyl cyclase activity of soluble guanylyl cyclase in intact cells.
Bähre H; Danker KY; Stasch JP; Kaever V; Seifert R
Biochem Biophys Res Commun; 2014 Jan; 443(4):1195-9. PubMed ID: 24380860
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.
Chien WL; Liang KC; Teng CM; Kuo SC; Lee FY; Fu WM
Mol Pharmacol; 2003 Jun; 63(6):1322-8. PubMed ID: 12761342
[TBL] [Abstract][Full Text] [Related]
37. Involvement of YC-1 in extracellular signal-regulated kinase action in rat cremasteric muscle.
Hsieh YH; Huang SS; Day YJ; Wei FC; Hung LM
J Pharm Pharmacol; 2010 Dec; 62(12):1746-52. PubMed ID: 21054401
[TBL] [Abstract][Full Text] [Related]
38. Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat.
Wegener JW; Gath I; Förstermann U; Nawrath H
Br J Pharmacol; 1997 Dec; 122(7):1523-9. PubMed ID: 9421305
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory phosphorylation of soluble guanylyl cyclase by muscarinic m2 receptors via Gbetagamma-dependent activation of c-Src kinase.
Murthy KS
J Pharmacol Exp Ther; 2008 Apr; 325(1):183-9. PubMed ID: 18180373
[TBL] [Abstract][Full Text] [Related]
40. Novel approaches and opportunities for cardioprotective signaling through 3',5'-cyclic guanosine monophosphate manipulation.
Bice JS; Burley DS; Baxter GF
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):269-82. PubMed ID: 24572031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
